内脏肥胖对左心室透气功能障碍的病理生理学贡献
Reika Nagata1,2, Masaru Obokata1, Miki Matsui2
1Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan.
Journal of cardiovascular development and disease
|June 27, 2023
概括
增加内脏脂肪,但不是皮下脂肪,与左心室扩张性功能障碍 (LVDD) 有关. 这一发现表明内脏脂肪有助于LVDD病理生理学.
科学领域:
- 心脏病学 心脏病学
- 代谢综合征是代谢综合征的一种.
- 医疗成像医学成像
背景情况:
- 内脏脂肪释放炎症性细胞因子,可能导致心力衰竭与保存的喷射分数 (HFpEF).
- 关于内脏脂肪异常如何影响左心室扩张功能障碍 (LVDD) 的数据有限.
研究的目的:
- 调查内脏脂肪量与左心室扩张功能障碍 (LVDD) 之间的关系.
- 探索内脏脂肪在LVDD病理生理学的作用.
主要方法:
- 研究了77名接受腹部手术的患者 (44名患有LVDD,33名对照).
- 通过腹部CT扫描评估内脏和皮下脂肪区域.
- 在内脏脂肪样本中测量了炎症性细胞因子的mRNA水平.
主要成果:
- 与对照组相比,患有LVDD的患者的内脏脂肪区域显著增加.
- 内脏脂肪面积与BNP水平,LV质量指数和腹转移功能参数 (米特拉e'速度,E/e'比率) 相对相关.
- 两组之间没有发现内脏脂肪组织细胞因子mRNA表达的显著差异.
结论:
- 升高的内脏脂肪与左心室扩张性功能障碍 (LVDD) 有关.
- 内脏脂肪积累可能在LVDD中发挥病理生理作用.
相关概念视频
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Mitral Regurgitation I: Introduction
19
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
19
Mitral Stenosis I: Introduction
18
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
18
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11


